Related Experiment Video

Updated: Nov 27, 2025

Measurement of Chitinase Activity in Biological Samples
03:32

Measurement of Chitinase Activity in Biological Samples

Published on: August 22, 2019

10.6K

Clinical significance of chitotriosidase in outpatients with advanced heart failure

Sara Cetin Sanlialp1, Gokay Nar2, Hande Senol3

  • 1The Department of Cardiology, Servergazi State Hospital, Denizli, Turkey saracetin@hotmail.com.tr.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|December 4, 2020
PubMed

Insights

Plasma chitotriosidase (CHIT) levels are elevated in chronic heart failure (CHF) patients and correlate with N-terminal pro brain natriuretic peptide (NT-proBNP). This suggests CHIT may aid in diagnosing and assessing CHF severity.

Area of Science:

  • Biochemistry
  • Cardiology
  • Immunology

Background:

  • Plasma chitotriosidase (CHIT) is an inflammatory marker elevated in various diseases.
  • Chronic heart failure (CHF) involves inflammatory processes.
  • The role of CHIT in CHF diagnosis and severity remains unexplored.

Purpose of the Study:

  • To investigate the association between plasma CHIT levels and CHF.
  • To evaluate CHIT's potential role in diagnosing CHF.
  • To assess CHIT's correlation with CHF severity.

Main Methods:

  • Plasma CHIT and N-terminal pro brain natriuretic peptide (NT-proBNP) levels were measured using ELISA in 36 CHF patients and 27 controls.
  • CHF patients were categorized into ischemic (IHF) and non-ischemic (NIHF) groups.
  • Statistical analysis was performed to compare CHIT and NT-proBNP levels between groups and assess correlations.

Main Results:

  • Plasma CHIT and NT-proBNP levels were significantly higher in CHF patients compared to controls (p<0.001).
  • Both CHIT and NT-proBNP levels were elevated in IHF compared to NIHF (p=0.002 for CHIT, p=0.001 for NT-proBNP).
  • A strong positive correlation was observed between plasma CHIT and NT-proBNP levels (r=0.969, p<0.001).

Conclusions:

  • Plasma CHIT levels are increased in patients with CHF.
  • Elevated CHIT levels in CHF correlate strongly with NT-proBNP, a known HF biomarker.
  • CHIT shows potential as a diagnostic and prognostic marker for CHF.

Keywords:
biomarkersheart failureimmunityinnate

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.7K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
120
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
100
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
187
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
341
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
957
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
204